Banque Cantonale Vaudoise Acquires 25,886 Shares of Edwards Lifesciences Co. (NYSE:EW)

Banque Cantonale Vaudoise increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 46.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 81,111 shares of the medical research company’s stock after purchasing an additional 25,886 shares during the period. Banque Cantonale Vaudoise’s holdings in Edwards Lifesciences were worth $5,353,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Crewe Advisors LLC bought a new stake in Edwards Lifesciences in the first quarter worth $28,000. First Community Trust NA bought a new position in Edwards Lifesciences during the second quarter valued at $29,000. Webster Bank N. A. bought a new position in Edwards Lifesciences during the second quarter valued at $39,000. Versant Capital Management Inc increased its position in Edwards Lifesciences by 206.3% during the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 326 shares during the last quarter. Finally, HHM Wealth Advisors LLC bought a new position in Edwards Lifesciences during the second quarter valued at $55,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. This trade represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,000 shares of company stock worth $2,657,000. 1.27% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

EW stock opened at $69.89 on Tuesday. The firm has a market cap of $41.22 billion, a price-to-earnings ratio of 10.09, a PEG ratio of 3.81 and a beta of 1.12. The firm has a 50-day simple moving average of $67.53 and a two-hundred day simple moving average of $76.02. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same period last year, the firm posted $0.59 EPS. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Citigroup cut their price objective on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research report on Tuesday, October 1st. TD Cowen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price objective for the company from $100.00 to $70.00 in a research report on Thursday, July 25th. Robert W. Baird cut their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. UBS Group cut their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Tuesday, September 10th. Finally, Baird R W cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Seventeen research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.